ARG63099

anti-SOCS3 antibody [SO1]

anti-SOCS3 antibody [SO1] for Western blot and Human

Cancer antibody; Developmental Biology antibody; Gene Regulation antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody

Overview

Product Description Mouse Monoclonal antibody [SO1] recognizes SOCS3
Tested Reactivity Hu
Tested Application WB
Specificity The clone SO1 reacts with SOCS3, an intracellular cytokine signaling inhibitor.
Host Mouse
Clonality Monoclonal
Clone SO1
Isotype IgG2b
Target Name SOCS3
Immunogen Full-length SOCS3 protein.
Conjugation Un-conjugated
Alternate Names SOCS-3; Cish3; CIS-3; Suppressor of cytokine signaling 3; SSI-3; SSI3; CIS3; Cytokine-inducible SH2 protein 3; STAT-induced STAT inhibitor 3; ATOD4

Application Instructions

Application Suggestion
Tested Application Dilution
WBAssay-dependent
Application Note WB: Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with reducing Laemmli SDS-PAGE sample buffer. Application note: Reducing condition.
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.
Positive Control WB: HeLa

Properties

Form Liquid
Purification Purified from hybridoma culture supernatant by protein A-affinity chromatography.
Purity > 95% (by SDS-PAGE)
Buffer PBS (pH 7.4) and 15 mM Sodium azide
Preservative 15 mM Sodium azide
Concentration 1 mg/ml
Storage Instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Database Links

GeneID: 9021 Human SOCS3

Swiss-port # O14543 Human Suppressor of cytokine signaling 3

Gene Symbol SOCS3
Gene Full Name suppressor of cytokine signaling 3
Background SOCS3 (suppressor of cytokine signaling 3), also known as CIS3 (cytokine-inducible SH2 protein 3) is a negative regulator of particular cytokine signaling pathways. SOCS3 is induced by a variety of cytokines and other stimuli, such as erythropoietin, leptin and lipopolysaccharides and inhibits tyrosinkinase activity of JAK kinases, or e.g. JNK phosphorylation. SOCS3 modulates cytokine-mediated and neoplastic-proliferative responses and is involved also in maintaining leukocytes in quiescent state until antigen stimulation.
Function SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST (By similarity). [UniProt]
Research Area Cancer antibody; Developmental Biology antibody; Gene Regulation antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody
Calculated MW 25 kDa
PTM Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1.

Clone References

Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.

Neuwirt H et al.
Endocr Relat Cancer.,  (2007)

publication_link

 

hr_line